A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule

A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug

This study investigates how gastrointestinal toxicity affects discontinuation of medication given to patients with osteoarthritis in routine clinical practice.

Inclusion Criteria:

• Minimum 20- year-old patients diagnosed with osteoarthritis
• Within 2 weeks prior to participation, not taken anti-inflammatory analgesic drug such as the Shinbaro Capsule, Celecoxib Capsule and NSAIDs(non-steroidal anti-inflammatory drugs)
• Written consent form voluntarity

Exclusion Criteria:

• Diagnosed with disease that may affect measurement of efficacy clinically
• Diagnosed with clinically significant phycological disorder, and taking medication
• Participated in a clinical trial within 4 weeks
• Pregnant or lactating woman
• History of malignant disease within the previous 5 years
• Patients who seem not to participate in the study at investigator's discretion